Clinical Trial Search

Primary: Change in Headache Days/Month After 4 Years Compared to Baseline — 6.6 headache days/month

Primary: Headache Days — 7.2; 4.2; 1.6 days/month — p=0.056

Primary: Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4 — -6.85; -3.66 days/month — p=<0.0001

Primary: Frequency of Moderate to Severe Headache Days — 9.3; 9.1 days

Primary: Number of Participants With Absence of Medication Overuse Headaches (MOH) at Month 6 — 102; 117; 134 Participants — p=0.13

Primary: Visual Analog Scale — 8.3; 8.4; 5.3; 5.3 units on a scale

Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants

Primary: 0-10 Pain Scale on Which 0 = no Pain and 10= the Worst Pain Imaginable — 5.2; 3.8 units on a scale

Primary: Change in Pain Score — 3.8; 5.1 units on a scale

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS) — 1.38; 1.22 units on a scale — p=0.674

Primary: Reduction in Headache Intensity — 6; 4; 1; 3 Participants

Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…

Primary: Long-term Safety of Chronic Intermittent Use of AXS-07 — 293; 118; 8; 10 Participants

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Change in Pain Score at 60 Minutes — 4; 5 score on a scale

Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants

Primary: Number of Participants With Response to Occipital Nerve Block in Pregnancy — 20; 16 Participants — p=0.30

Primary: Time to Relief (Min) — 92.2; 83.9; 35.4 Minutes

Primary: Numerical Rating Scale — 4.1; 4.3 units on a scale

Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01

Primary: Percentage of Participants Admitted to the Hospital for Headache — 6.0; 2.1 percentage of participants

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days

Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants

Primary: Number of Participants With Sustained Headache Relief — 12 Participants

Primary: Number of Participants With Adequate Relief of Headache as a Measure of Efficacy — 34; 32 Participants — p=0.14

Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale

Primary: Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period — 48.1; 48.9 percentage of participants — p=0.954

Primary: Change in Pain Scores Based on Patient Questionnaire — -2.95; -1.79; -4.49; -2.65 units on a scale of 1-10

Primary: Headache Days — 23.64; 24.33 Days — p=0.83